ArticleACS biomaterials science & engineering2025
Bioprinted Hormone-Responsive Bilayer Model of Human Endometrium for Embryo Implantation Studies.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Engineering the human endometrium at the intersection of development and reproduction.Nature biomedical engineering · 2026Review
- Hydrogel-Based Systems in Intrauterine Adhesions: Bridging the Gap from Bench to Bedside.Advanced healthcare materials · 2026Review
- Engineering human endometrial model systems in reproductive health and disease.npj biomedical innovations · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implantation failure is a major challenge in reproductive medicine, with two-thirds of cases attributed to poor uterine receptivity. Current models have limited utility in capturing the complexities of the endometrium. This study introduces a novel bioprinted endometrial model with epithelial and stromal cells in a bilayer structure, designed to replicate the hormone-regulated endometrial environment and support embryo implantation studies. Alginate-based bioink formulations, cross-linked with calcium chloride or calcium gluconate, were optimized for 3D cell bioprinting, based on key parameters: reduced spreading ratio, lower printed line width standard deviation (SD), slower degradation rates, and enhanced cell viability. Human endometrial epithelial (RL95-2) and stromal (T HESCs) cell lines were encapsulated in the bioink and bioprinted in a bilayer structure: Clear stratification mimicking the layered architecture of native endometrium was confirmed using fluorescent microscopy. Sequential hormonal treatments with estradiol (proliferative phase), followed by estradiol and progesterone (secretory phase) highlighted the model's hormone-responsiveness. Estradiol significantly enhanced cell viability by day 2, while progesterone reduced cell viability by day 5, consistent with adaptation to the proliferative and secretory phases. Hormone-treated constructs displayed significantly lower E-cadherin expression, higher mRNA expression of various integrins and of vascular endothelial growth factor (VEGF), and reduced metalloproteinase (MMP)-2 secretion after 5 days, mirroring in vivo endometrial remodeling under progesterone influence. JAR spheroids, representing human blastocyst cells, adhered to and infiltrated the epithelial layer of the hormone-treated, bilayered model, effectively simulating embryo implantation. This bioprinted bilayer endometrial model represents a significant advancement in reproductive biology. It offers a platform for studying in vitro endometrial receptivity and implantation and paves the way for personalized treatment approaches in recurrent implantation failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.